Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…Modulation of autophagy and neuroinflammation by Niclosamide in MPTP Induced- Parkinson’s disease model
Objective: The current investigation aimed to investigate the neuroprotective effect of niclosamide (NI) on autophagy and neuroinflammatory pathways in Parkinson’s disease (PD). Background: Autophagy dysregulation…Neurofilament light chain, tau-PET and microglia-PET predict clinical progression in amyloid-negative corticobasal syndrome
Objective: A head-to-head comparison of neuroimaging (tau-PET, microglia-PET, structural MRI) and plasma biomarker Neurofilament light chain (NfL) as prognostic tools for longitudinal clinical trajectories in…Perception of the subjective visual vertical in subjects with cervical dystonia
Objective: The Aim of the study was to assess:1.) if the perception of the visual vertical (VV) is impaired in subjects with cervical dystonia (CDsub),…Women and PD: experienced changes in parkinson symptoms after menopause
Objective: This study aimed to gain insight into changes in parkinson (PD) symptoms experienced by women after menopause. Background: Although most people are diagnosed with…Preliminary evidence for evolution of myoinositol and N-acteylaspartate as biomarkers of disease severity in early-stage multiple system atrophy
Objective: To quantify the longitudinal evolution of metabolic indicators of gliosis and neuronal integrity in patients with multiple system atrophy (MSA) over one year. Background:…Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington’s disease
Objective: To prove the efficacy and safety of dextromethorphan/quinidine 20mg/10mg (Nuedexta®) in patients with irritability due to HD. Background: Irritability is one of HD's most…Screening risk of falls in Parkinson’s disease population living in underserved areas
Objective: To verify the feasibility of the Balance-App to assess the risk of falls in the PD population living in underserved areas. Background: The screening…Development of a patient journey map for people living with Parkinson’s disease
Objective: Develop a Motor Fluctuations Patient Journey Map (MFPJM) for people with Parkinson’s disease (PwP) to describe the holistic experience from pre-diagnosis through long-term treatment,…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…
- « Previous Page
- 1
- …
- 441
- 442
- 443
- 444
- 445
- …
- 1734
- Next Page »